Microbot Medical Inc
microbotmedical.comMicrobot Medical Inc. (NASDAQ: MBOT) is a pre-revenue medical device company developing robotic surgical systems for endovascular procedures. The company generates no product revenue as of fiscal year ended December 31, 2025, and finances operations through equity offerings, potential licensing or collaboration arrangements, grants, and debt financings. Its lead product candidate is the LIBERTY Endovascular Robotic Surgical System, which remains subject to regulatory clearance. Harel Gadot serves as President, Chief Executive Officer, and Chairman, as of March 26, 2026. The company is incorporated in Delaware and has operations with Israeli roots, including prior activity under Microbot Israel. No dividends have been paid, and none are anticipated. The company does not have committed external funding sources and expects continued losses until, if ever, it reaches profitability.
Products & Services
Lead product candidate: LIBERTY Endovascular Robotic Surgical System. The product was not commercially approved as of the filing date (March 26, 2026) and is subject to FDA 510(k) clearance.
Revenue Model
No product revenue is disclosed in the FY2025 10-K. The company funds operations through equity offerings, including potential at-the-market offerings, licensing or collaboration arrangements, grants, and debt financings.
Customers & Markets
Target end markets include hospitals and medical institutions performing endovascular procedures. Acceptance by the medical community, patients, and third-party payors is identified as a condition for commercial success. No customer revenue is disclosed for FY2025.
Geographic Exposure
Operations span the United States and Israel. Regulatory pathways referenced include the FDA (United States) and Israel's Ministry of Health. Israeli-manufactured device registration processes are described in the filing.
Financial Snapshot
Loading...
